Engineering interferons and interleukins for cancer immunotherapy

Adv Drug Deliv Rev. 2022 Mar:182:114112. doi: 10.1016/j.addr.2022.114112. Epub 2022 Jan 24.

Abstract

Cytokines are a class of potent immunoregulatory proteins that are secreted in response to various stimuli and act locally to regulate many aspects of human physiology and disease. Cytokines play important roles in cancer initiation, progression, and elimination, and thus, there is a long clinical history associated with the use of recombinant cytokines to treat cancer. However, the use of cytokines as therapeutics has been limited by cytokine pleiotropy, complex biology, poor drug-like properties, and severe dose-limiting toxicities. Nevertheless, cytokines are crucial mediators of innate and adaptive antitumor immunity and have the potential to enhance immunotherapeutic approaches to treat cancer. Development of immune checkpoint inhibitors and combination immunotherapies has reinvigorated interest in cytokines as therapeutics, and a variety of engineering approaches are emerging to improve the safety and effectiveness of cytokine immunotherapy. In this review we highlight recent advances in cytokine biology and engineering for cancer immunotherapy.

Keywords: Cell therapy; Cytokine engineering; Cytokines; Drug delivery; Immune signaling; Ligand-receptor interaction; Protein engineering.

Publication types

  • Review

MeSH terms

  • Bioengineering / methods*
  • Biomimetics
  • Drug Delivery Systems / methods
  • Genetic Engineering / methods
  • Humans
  • Hydrogen-Ion Concentration
  • Interferons / adverse effects
  • Interferons / metabolism
  • Interferons / pharmacokinetics
  • Interferons / pharmacology*
  • Interleukins / adverse effects
  • Interleukins / metabolism
  • Interleukins / pharmacokinetics
  • Interleukins / pharmacology*
  • Neoplasms / drug therapy
  • Neoplasms / pathology*

Substances

  • Interleukins
  • Interferons